Ann Arbor's Asalyxa Bio Raises $2 Million To Start Clinical Trials for Neutrophil-Targeting Drug Delivery Tech

Asalyxa Bio, Inc., a biopharmaceutical startup developing nano-engineered, immune cell-targeted therapeutics, just announced the closing of…